Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

Blood (2025) 146 (Supplement 1): 4074.

https://doi.org/10.1182/blood-2025-4074

Published: 2025

Journal Articles

Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)

Rui Lv, Tingyu Wang, Yuting Yan, Tengteng Yu, Xiong Wenjie, Ying Yu, Qi Wang, Shuaishuai Zhang, Hesong Zou, Shuhui Deng, Yan Xu, Dehui Zou, Liang Huang, Gang An, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 5379.

https://doi.org/10.1182/blood-2025-5379

Published: 2025

Journal Articles

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Blood (2025) 146 (Supplement 1): 2299.

https://doi.org/10.1182/blood-2025-2299

Published: 2025

Journal Articles

Clinical characteristics and prognostic analysis of 52 cases of ALK-positive anaplastic large cell lymphoma

Wen Zhang, Wei LIU, Ting Xie, Tingyu Wang, Xiong Wenjie, Hesong Zou, Yi Wang, Shuhua Yi, Wenyang Huang, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 7165.

https://doi.org/10.1182/blood-2025-7165

Published: 2025

Journal Articles

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

Blood (2025) 146 (Supplement 1): 4015.

https://doi.org/10.1182/blood-2025-4015

Published: 2025

Journal Articles

BCMA CAR T-cell therapy in newly diagnosed transplant-ineligible multiple myeloma: An open label, single-arm, phase 2 study (CAREMM-001)

Wenqiang Yan, Chenxing Du, Hesong Zou, Shuaishuai Zhang, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 2293.

https://doi.org/10.1182/blood-2025-2293

Published: 2025

Journal Articles

Pola-R-edch shows high response rates in high-risk aggressive B-cell lymphomas or PMBCL: A phase 2 study

Wei LIU, Yi Wang, Huimin Liu, Qi Wang, Hesong Zou, Yan Xu, Wenyang Huang, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 3683.

https://doi.org/10.1182/blood-2025-3683

Published: 2025

Journal Articles

Metabolomics profiling and machine learning prediction of efficacy and prolonged cytopenia in patients with large B-cell lymphoma undergoing CAR-T therapy

Hesong Zou, Chen Jia, Wei LIU, Huimin Liu, Yi Wang, Yan Xu, Shuhua Yi, Gang An, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 1938.

https://doi.org/10.1182/blood-2025-1938

Published: 2025

Journal Articles

BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002)

Wenqiang Yan, Chenxing Du, Hesong Zou, Shuaishuai Zhang, Shuhui Deng, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 257.

https://doi.org/10.1182/blood-2025-257

Published: 2025

Journal Articles

A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma

Huimin Liu, Hesong Zou, Wei Liu, Wenyang Huang, Shuhui Deng, Rui Lv, Weiwei Sui, Yan Xu, Shuhua Yi, Tingyu Wang, Mingwei Fu, Gang An, Yaozhong Zhao, Lugui Qiu, Dehui Zou

Blood (2022) 140 (Supplement 1): 10585–10586.

https://doi.org/10.1182/blood-2022-163258

Published: 2022

Journal Articles

Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial

Wei Liu, Hesong Zou, Yan Xu, Huimin Liu, Chenxing Du, Rui Lv, Wenyang Huang, Weiwei Sui, Shuhua Yi, Lulu Lv, Lugui Qiu, Jianxiang Wang, Dehui Zou

Blood (2022) 140 (Supplement 1): 7472–7473.

https://doi.org/10.1182/blood-2022-166451

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Clinical characteristics and prognostic analysis of 52 cases of ALK-positive anaplastic large cell lymphoma

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

BCMA CAR T-cell therapy in newly diagnosed transplant-ineligible multiple myeloma: An open label, single-arm, phase 2 study (CAREMM-001)

Pola-R-edch shows high response rates in high-risk aggressive B-cell lymphomas or PMBCL: A phase 2 study

Metabolomics profiling and machine learning prediction of efficacy and prolonged cytopenia in patients with large B-cell lymphoma undergoing CAR-T therapy

BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002)

A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma

Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only